ASCLETIS
Ascletis is a joint venture between U.S. and Chinese entrepreneurs aimed at building a global specialty therapeutics business dedicated to discovering and developing important new treatments for cancer and infectious diseases. Ascletis leverages U.S./European innovation and pharmaceutical/biotech strategic experience and China's capital efficiency with a goal of establishing in the near term a sustainable business and accelerated revenues through the in-licensing, late-stage clinical development, and commercialization of new medicines for the growing Chinese pharmaceutical marketplace. At the same time, the company is building long-term value through the discovery, demonstration of clinical proof-of-concept, and global partnering of novel therapeutics for life-threatening diseases.
ASCLETIS
Social Links:
Industry:
Health Care Medical Therapeutics
Founded:
2011-01-01
Address:
Chapel Hill, North Carolina, United States
Country:
United States
Website Url:
http://www.ascletis.com
Total Employee:
251+
Status:
Active
Contact:
1-919-328-0212
Total Funding:
255 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Content Delivery Network Pound Sterling Apple Mobile Web App Capable Japanese Yen Apple Mobile Web App Status Bar Style Baidu Analytics China Ministry Of Public Security
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apogenix
Apogenix is a biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases.
Autotelic
Autotelic uses therapeutic drug monitoring to enhance the development of therapeutics.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Theraclone Sciences
Theraclone Sciences is a biotech company developing novel therapeutic antibodies for the treatment of infectious diseases and inflammation.
Viking Therapeutics
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Tasly Pharmaceutical
Tasly Pharmaceutical investment in Series B - Ascletis
Focus Media
Focus Media investment in Series B - Ascletis
QianHai Equity Investment
QianHai Equity Investment investment in Series B - Ascletis
WTT Investment
WTT Investment investment in Series B - Ascletis
Goldman Sachs
Goldman Sachs investment in Series B - Ascletis
C-Bridge Capital
C-Bridge Capital investment in Series B - Ascletis
Goldman Sachs
Goldman Sachs investment in Venture Round - Ascletis
C-Bridge Capital
C-Bridge Capital investment in Series B - Ascletis
Tasly Pharmaceutical
Tasly Pharmaceutical investment in Series B - Ascletis
Pavillion Capital
Pavillion Capital investment in Series B - Ascletis
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-02-11 | Sagimet Biosciences | Ascletis investment in Venture Round - Sagimet Biosciences | 80 M USD |
| 2019-08-05 | Sagimet Biosciences | Ascletis investment in Series E - Sagimet Biosciences | 7 M USD |
| 2019-02-13 | Sagimet Biosciences | Ascletis investment in Series E - Sagimet Biosciences | 18 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-13 | Ascletis Announces Appointment of Mr. John P. Gargiulo, Former North America President and CEO of Daiichi Sankyo, as Chief Business Officer |
Official Site Inspections
http://www.ascletis.com Semrush global rank: 5.18 M Semrush visits lastest month: 1.51 K
- Host name: 47.75.123.183
- IP address: 47.75.123.183
- Location: Central Hong Kong
- Latitude: 22.2909
- Longitude: 114.15
- Timezone: Asia/Hong_Kong
More informations about "Ascletis"
Ascletis Pharma Inc.
Apr 2, 2025 Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with โฆSee details»
Ascletis Pharma Inc.
ๆไปฌไธบๅๅทฅๆไพๅ ทๆ็ซไบๅ็่ช่ตใ็ฆๅฉใๅฆๆจๆๆๅ ็ๆญ็คผ๏ผ่ฏทๅฐ็ฎๅๅ้่ณ [email protected]๏ผ ๆไปฌๅฐๅฐฝๅฏ่ฝๅฐ็ปๅๆจ็ไธไธๅๅ ฌๅธๅๅฑ้ๆฑ๏ผไธบๆจๆไพๆพ้ฃๆขฆๆณ็่ๅฐใSee details»
Ascletis - Crunchbase Company Profile & Funding
Ascletis leverages U.S./European innovation and pharmaceutical/biotech strategic experience and China's capital efficiency with a goal of establishing in the near term a sustainable business โฆSee details»
Ascletis Pharma Company Profile | Management and Employees โฆ
To date, Ascletis has three marketed products, i.e. ritonavir tablets, GANOVO® and ASCLEVIR®, and 20 drug candidates in its R&D pipeline. The most advanced drug candidates include โฆSee details»
Ascletis Pharma (ASCLF) Company Profile & Description - Stock โฆ
Apr 24, 2025 Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland โฆSee details»
Ascletis Company Profile - Office Locations, Competitors ... - Craft
Ascletis focuses on building a global specialty therapeutics business dedicated to discovering and developing important new treatments for cancer and infectious diseases.We leverage โฆSee details»
Ascletis | Biotech Careers
Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), a global platform covering the entire value chain from discovery and development to โฆSee details»
Ascletis - VentureRadar
Ascletis Pharma Inc. is dedicated to developing and commercializing innovative drugs targeting viral diseases, NASH (non-alcoholic steatohepatitis), and cancer. The company focuses on โฆSee details»
Ascletis - Funding, Financials, Valuation & Investors - Crunchbase
Ascletis is registered under the ticker HKG:1672.HK . Their stock opened with HK$14.00 in its Aug 1, 2018 IPO. Ascletis is funded by 8 investors. Tasly Pharmaceutical and Focus Media โฆSee details»
Ascletis - PharmaBoardroom
Jun 20, 2019 Ascletis is an innovative R&D driven biotech with two commercial products and listed on the Hong Kong Stock Exchange. Ascletisโ mission is to address unmet medical needs โฆSee details»
Ascletis' Leadership Team - Team members and org chart - The Org
Other teams at Ascletis. View all +1. CEO and Executive Team. 4 members. JG. LH. YW. Board of Directors. 3 members. The Org helps you hire great candidates. It takes less than ten โฆSee details»
Ascletis Pharmaceuticals - VentureRadar
" Ascletis focuses on building a global specialty therapeutics business dedicated to discovering and developing important new treatments for cancer and infectious diseases. We leverage โฆSee details»
Ascletis Pharma Inc.
Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to GMP manufacturing. Led โฆSee details»
Ascletis - Contacts, Employees, Board Members, Advisors & Alumni
Ascletis is a specialty therapeutics company developing therapeutics for the treatment of cancer and infectious diseases.See details»
Ascletis Pharma - Overview, News & Similar companies - ZoomInfo
Jun 15, 2022 Who is Ascletis Pharma. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and d โฆSee details»
Ascletis - Company Profile & Staff Directory - ContactOut
Ascletis is a joint venture between U.S. and Chinese entrepreneurs aimed at building a global specialty therapeutics business dedicated to discovering and developing important new โฆSee details»
Ascletis Pharma Inc.
Ascletis has filed multiple patent applications globally for ASC10 and its use in viral diseases including monkeypox virus infection. Monkeypox virus is an orthopoxvirus that causes a โฆSee details»
Ascletis slashes funding for former core programs in pivot to obesity
Mar 26, 2025 Ascletis plans to further assess its primary biliary cholangitis prospect and seek opportunities to maximize the value of the program. Liver diseasesโ share of spending will fall โฆSee details»
Ascletis Announces Positive Topline Results of U.S. Phase Ib โฆ
Apr 22, 2025 Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to GMP โฆSee details»
Corporate Presentation - ascletis.com
Aug 27, 2021 NASH pipeline is owned by Gannex Pharma Co., Ltd., an independent biotech which is currently wholly-owned by Ascletis Pharma Inc.(1672.HK). 2. ASC40 is licensed from โฆSee details»